Cargando…

A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma

This systematic literature review describes adverse events (AEs) among patients with soft tissue sarcoma (STS) who received second-line or later anticancer therapies. Searches were conducted in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for studies of adults with advanced or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colosia, Ann, Khan, Shahnaz, Hackshaw, Michelle D., Oglesby, Alan, Kaye, James A., Skolnik, Jeffrey M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969544/ https://www.ncbi.nlm.nih.gov/pubmed/27516726 http://dx.doi.org/10.1155/2016/3597609

Ejemplares similares

Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review
por: Colosia, Ann D, et al.
Publicado: (2013)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment
por: Takada, Kohichi, et al.
Publicado: (2019)

Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population
por: Duh, Mei Sheng, et al.
Publicado: (2013)

Management of Advanced Adult Soft Tissue Sarcoma
por: Bramwell, Vivien H. C.
Publicado: (2003)

Systemic Therapy for Advanced Soft Tissue Sarcomas
por: Riedel, Richard F
Publicado: (2012)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Epidemiology, Treatment Patterns, and Outcomes of Metastatic Soft Tissue Sarcoma in a Community-Based Oncology Network
por: Chen, Clara, et al.
Publicado: (2014)

Brain Metastases in Soft Tissue Sarcomas: Case Report and Literature Review
por: Gupta, Tejpal, et al.
Publicado: (2005)

Epidemiology of Adult Soft-Tissue Sarcomas in Germany
por: Saltus, Catherine W., et al.
Publicado: (2018)

Margin Assessment in Soft Tissue Sarcomas: Review of the Literature
por: Sambri, Andrea, et al.
Publicado: (2021)

The adverse effect of an unplanned surgical excision of foot soft tissue sarcoma
por: Nishimura, Akinobu, et al.
Publicado: (2011)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Trabectedin for advanced soft tissue sarcomas: optimizing use
por: Reid, Alison, et al.
Publicado: (2014)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
por: Strassmann, Dennis, et al.
Publicado: (2021)

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas
por: Parikh, Rohan C., et al.
Publicado: (2018)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Superficial Soft-Tissue Sarcomas Rarely Require Advanced Soft-Tissue Reconstruction following Resection
por: Eward, William C., et al.
Publicado: (2017)

Immunoglobulin G Locus Events in Soft Tissue Sarcoma Cell Lines
por: Chen, Zhengshan, et al.
Publicado: (2011)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Advances in soft-tissue sarcoma – There are no mistakes, only lessons to learn!
por: Rastogi, Sameer, et al.
Publicado: (2019)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Yuan, Jin, et al.
Publicado: (2021)

Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas
por: Patel, Shreyaskumar R., et al.
Publicado: (1997)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Targeted therapies for the treatment of soft tissue sarcoma
por: Fuchs, Jeffrey W., et al.
Publicado: (2023)

Retroperitoneal soft tissue sarcoma
por: Zepeda, Ernesto, et al.
Publicado: (2007)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Soft Tissue Sarcomas of the Kidney
por: Köhle, Olivia, et al.
Publicado: (2015)

Bone and Soft Tissue Sarcoma
por: Ruggiero, Antonio
Publicado: (2020)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients
por: Stelzl, Adrian, et al.
Publicado: (2020)

Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services
por: Bae, Susie, et al.
Publicado: (2016)

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
por: Verschoor, Arie J, et al.
Publicado: (2014)

Symptom Burden, Survival and Palliative Care in Advanced Soft Tissue Sarcoma
por: Gough, Nicholas J., et al.
Publicado: (2011)

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mnj283k8b5jjr51jopjm49n6ud